{"gene":"APOC1","run_date":"2026-04-28T17:12:37","timeline":{"discoveries":[{"year":2004,"finding":"ApoC-I directly inhibits LPL-mediated TG-lipolysis in a dose-dependent manner in vitro, and increases plasma half-life of VLDL-TG particles in vivo; this LPL inhibition (not blockade of apoE-mediated hepatic lipoprotein receptors) is the principal mechanism by which apoC-I causes hypertriglyceridemia in APOC1 transgenic mice.","method":"In vitro LPL lipolysis assay with purified apoC-I; [3H]TG-VLDL particle clearance in vivo in APOC1 transgenic and apoE-deficient × APOC1 transgenic mice; lactoferrin-treatment to block hepatic clearance","journal":"Journal of lipid research","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstituted LPL inhibition assay plus multiple in vivo mouse models with orthogonal readouts; replicated conceptually in a second study (PMID:16537968)","pmids":["15576844"],"is_preprint":false},{"year":2006,"finding":"Endogenous apoC-I (at physiological levels) increases VLDL-TG and VLDL-cholesterol by two independent mechanisms: stimulating hepatic VLDL production and attenuating LPL lipolytic activity, as demonstrated in apoE-knockout mice with graded apoC-I gene doses.","method":"Comparison of apoe-/-apoc1-/-, apoe-/-apoc1+/-, and apoe-/-apoc1+/+ mice; hepatic VLDL-TG and VLDL-apoB production rates; [3H]TG-VLDL clearance by white adipose tissue; total postheparin plasma LPL activity","journal":"Journal of lipid research","confidence":"High","confidence_rationale":"Tier 2 — clean genetic dose-response KO model with multiple orthogonal metabolic readouts; extends and confirms PMID:15576844","pmids":["16537968"],"is_preprint":false},{"year":1976,"finding":"Synthetic apoC-I corresponding to the full 57-amino acid sequence activates lecithin:cholesterol acyltransferase (LCAT) to the same extent as native apoC-I, establishing apoC-I as an activator of LCAT.","method":"Solid-phase peptide synthesis of full-length apoC-I; LCAT activation assay comparing synthetic vs. native protein; lipid-binding studies with DMPC by ultracentrifugation","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstitution with synthetic protein and direct enzymatic assay","pmids":["179085"],"is_preprint":false},{"year":2007,"finding":"ApoC-I, when residing in HDL, promotes membrane fusion of HCV with target cells via direct interaction with the HCV surface; this enhancement requires the hypervariable region 1 (HVR1) of HCV E2 glycoprotein, and excess lipid-free apoC-I instead disrupts the viral membrane and abolishes infectivity.","method":"HCVcc and HCVpp infectivity assays; membrane fusion rate measurements; binding assays between apoC-I and HCV surface; HVR1 mutant viruses; lipid-free apoC-I dose-response experiments","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal functional assays (fusion rates, infectivity, binding, mutant analysis) in a single study","pmids":["17761674"],"is_preprint":false},{"year":2008,"finding":"The C-terminal amphipathic α-helix of apoC-I (residues 38–51) contains the major lipid-binding determinants; aromatic residues F42 and F46 are critical for phospholipid (DMPC) binding affinity and for formation of correctly shaped discoidal lipid-protein complexes.","method":"LC-MS/MS proteolysis protection assay; site-directed mutagenesis of F42 and F46 to Ala or Gly; DMPC binding affinity by Kd(app); sedimentation velocity analytical ultracentrifugation; transmission electron microscopy of discoidal complexes","journal":"Journal of lipid research","confidence":"High","confidence_rationale":"Tier 1 — mutagenesis combined with in vitro binding assays and structural characterization (TEM, AUC) in one study","pmids":["18984910"],"is_preprint":false},{"year":2005,"finding":"ApoC-I present in HDL constitutes a potent endogenous inhibitor of cholesteryl ester transfer protein (CETP); removal of rat apoC-I from HDL upon human apoA-I overexpression accounts for approximately two-thirds of the loss of CETP-inhibitory activity of HDL.","method":"Human apoA-I/CETP double-transgenic rat model; quantification of apoC-I in HDL; CETP activity assay with reconstituted lipoproteins; comparison of CETP inhibition between wild-type and transgenic HDL","journal":"Journal of lipid research","confidence":"Medium","confidence_rationale":"Tier 2 — in vivo genetic model with direct CETP activity measurement, but single-lab study","pmids":["16282639"],"is_preprint":false},{"year":2005,"finding":"ApoC-I secretion by human HepG2 hepatocytes is regulated post-transcriptionally by cellular cholesterol levels: increasing cellular cholesterol (via HDL/LDL loading) increases apoC-I secretion without changing apoC-I mRNA; statin-mediated cholesterol depletion reduces secretion; triglyceride loading decreases apoC-I secretion also without mRNA changes.","method":"HepG2 cell culture with varied lipid conditions (human serum, LPDS, Intralipid, cholesterol loading, statin treatment); apoC-I and apoE protein measured in cell lysates and media by ELISA; apoC-I mRNA by Northern/RT-PCR","journal":"Atherosclerosis","confidence":"Medium","confidence_rationale":"Tier 2 — multiple orthogonal conditions in cell culture with paired mRNA and protein measurement, single lab","pmids":["15694932"],"is_preprint":false},{"year":2004,"finding":"In maturing human SW872 liposarcoma (adipocyte-like) cells, increased intracellular cholesterol and triglyceride accumulation drives increased apoC-I and apoE secretion independently of extracellular lipids; long-term insulin treatment inhibits apoC-I secretion; apoC-I and apoE are differentially regulated at the transcriptional level.","method":"SW872 cell differentiation assay; apoC-I and apoE protein measured in cell lysates and media; cellular lipid quantification; insulin treatment; lipoprotein-deficient serum conditions; mRNA measurement","journal":"The Journal of nutrition","confidence":"Medium","confidence_rationale":"Tier 2 — multiple conditions with paired protein/mRNA readouts; single lab","pmids":["15514255"],"is_preprint":false},{"year":2020,"finding":"ApoC1 promotes metastasis of clear cell renal cell carcinoma (ccRCC) cells by activating the STAT3 signaling pathway and inducing EMT; ApoC1 packaged in tumor cell exosomes is transferred to vascular endothelial cells, where it also activates STAT3 to enhance metastasis; DPP-4 inhibition suppresses ApoC1-driven metastasis.","method":"ApoC1 knockdown/overexpression in ccRCC cell lines; transwell invasion/migration assays; EMT marker western blot; exosome isolation and transfer experiments; STAT3 phosphorylation western blot; DPP-4 inhibitor treatment","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 — multiple functional assays (invasion, EMT, exosome transfer, STAT3 activation) in single lab","pmids":["32826950"],"is_preprint":false},{"year":2022,"finding":"APOC1 promotes M2 macrophage polarization through interaction with CD163 and CD206; macrophages overexpressing APOC1 drive ccRCC metastasis by secreting CCL5; co-culture of RCC cells with macrophages induces TAM generation with M2 phenotype, which is blocked by APOC1 silencing.","method":"Single-cell RNA sequencing; APOC1 silencing in macrophages; co-culture of RCC cells with macrophages; CCL5 ELISA; co-immunoprecipitation of APOC1 with CD163 and CD206","journal":"Pharmacological research","confidence":"Medium","confidence_rationale":"Tier 2-3 — co-IP identifies binding partners, functional assays confirm polarization and CCL5 secretion; single lab","pmids":["35914680"],"is_preprint":false},{"year":2022,"finding":"Inhibition of APOC1 reverses M2-to-M1 macrophage polarization via the ferroptosis pathway in tumor-associated macrophages from HCC; APOC1-/- mice show reduced tumor growth with increased CD8+ T cells and M1 macrophages and decreased M2 macrophages.","method":"scRNA-seq; APOC1-/- C57BL/6 mouse tumor model; mass spectrometry immune cell profiling; ferroptosis pathway analysis","journal":"Redox biology","confidence":"Medium","confidence_rationale":"Tier 2 — in vivo genetic KO model plus single-cell transcriptomics, but mechanistic link to ferroptosis not fully reconstituted","pmids":["36108528"],"is_preprint":false},{"year":2023,"finding":"APOC1 interacts directly with MTCH2 (mitochondrial carrier homolog 2) in osteosarcoma cells; APOC1 knockdown elevates oxidative phosphorylation and decreases the Warburg effect, and MTCH2 overexpression rescues these metabolic effects, placing APOC1 upstream of MTCH2 in the control of cancer cell metabolism.","method":"Co-immunoprecipitation of APOC1 with MTCH2; APOC1 siRNA knockdown; CCK-8 and TUNEL apoptosis assays; Warburg effect measurement (extracellular lactate, OCR); rescue experiments with MTCH2 overexpression","journal":"Experimental and therapeutic medicine","confidence":"Medium","confidence_rationale":"Tier 2-3 — co-IP confirms interaction; metabolic rescue experiments establish functional hierarchy; single lab","pmids":["36911382"],"is_preprint":false},{"year":2024,"finding":"M2 macrophage exosome-derived Apoc1 promotes ferroptosis resistance in osteosarcoma by inhibiting the interaction of USP40 deubiquitinase with ACSF2, thereby increasing ACSF2 ubiquitination and proteasomal degradation.","method":"M2 macrophage exosome isolation and co-culture with OS cells; shApoc1 knockdown; erastin ferroptosis induction; co-immunoprecipitation of Apoc1, ACSF2, and USP40; proteasomal inhibitor MG132; cyclohexanone protein synthesis inhibition","journal":"Molecular carcinogenesis","confidence":"Medium","confidence_rationale":"Tier 2 — co-IP with multiple partners and functional rescue experiments; single lab","pmids":["39041949"],"is_preprint":false},{"year":2024,"finding":"APOC1 binds directly to STAT3 in cardiomyocytes and increases phospho-STAT3 (p-STAT3) in the nucleus, activating the STAT3 signaling pathway to promote inflammation and apoptosis in coronary microembolization-induced myocardial injury.","method":"Co-immunoprecipitation of APOC1 with STAT3; immunofluorescence for p-STAT3 subcellular localization; western blot for pathway proteins; LPS-treated primary cardiomyocyte model; APOC1 overexpression rescue of STDP effects","journal":"Aging","confidence":"Medium","confidence_rationale":"Tier 2-3 — co-IP demonstrates direct APOC1-STAT3 binding; functional consequence shown in cell model; single lab","pmids":["38771126"],"is_preprint":false},{"year":2024,"finding":"Apoc1 knockdown in renal tubular epithelial cells alleviates high-glucose-induced oxidative stress and apoptosis by binding to and regulating Clusterin; Clusterin silencing blocks the protective effects of Apoc1 knockdown, placing Apoc1-Clusterin interaction as the mechanistic axis.","method":"Co-immunoprecipitation of Apoc1 with Clusterin in HK-2 cells; CCK-8 viability; DCFH-DA ROS staining; MDA/SOD assays; TUNEL apoptosis; western blot; DN mouse model with immunofluorescence","journal":"Cell biochemistry and biophysics","confidence":"Medium","confidence_rationale":"Tier 2-3 — co-IP confirms binding; functional rescue/epistasis by dual KD; single lab","pmids":["39630345"],"is_preprint":false},{"year":2023,"finding":"APOC1 silencing suppresses breast cancer growth and metastasis by inhibiting the MAPK/ERK kinase pathway and restraining NF-κB-driven transcription of pro-metastatic target genes; nanoparticle-delivered siAPOC1 recapitulates these effects in orthotopic and liver metastasis mouse models.","method":"APOC1 siRNA knockdown in breast cancer cell lines; western blot for ERK/MAPK and NF-κB pathway proteins; in vitro invasion/migration assays; GSH-responsive NP-siAPOC1 in orthotopic and liver metastasis mouse models","journal":"Science China. Life sciences","confidence":"Medium","confidence_rationale":"Tier 2 — in vitro pathway analysis combined with in vivo mouse model; single lab","pmids":["37668862"],"is_preprint":false},{"year":2023,"finding":"The lncRNA DLEU1 recruits the histone methyltransferase SMYD2 to the APOC1 promoter, inducing H3K4me3 modification and thereby upregulating APOC1 transcription, which in turn promotes gastric cancer cell proliferation and glycolysis.","method":"RIP and RNA pulldown (DLEU1-SMYD2 interaction); ChIP-PCR (SMYD2 binding to APOC1 promoter and H3K4me3 modification); ectopic expression and knockdown of DLEU1, SMYD2, APOC1; measurement of glycolytic parameters (ECAR, OCR, lactate, GLUT1/HK2/LDHA); xenograft mouse model","journal":"Translational oncology","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP and RIP establish epigenetic mechanism; functional rescue confirms pathway; single lab","pmids":["37478669"],"is_preprint":false},{"year":2022,"finding":"ZNF460 transcriptionally activates APOC1 by binding to the APOC1 promoter, and ZNF460-driven APOC1 upregulation promotes EMT and progression of gastric cancer cells.","method":"ChIP assay and luciferase reporter for ZNF460 binding to APOC1 promoter; ZNF460 knockdown and APOC1 rescue; EMT marker analysis; invasion/migration assays; xenograft tumor growth in vivo","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 2 — direct promoter binding established by ChIP + luciferase reporter; functional rescue confirms axis; single lab","pmids":["36563923"],"is_preprint":false},{"year":2025,"finding":"FOXM1 transcriptionally activates APOC1 by directly binding its promoter; the FOXM1/APOC1 axis drives cervical cancer cell proliferation, EMT, invasion, and M2 macrophage polarization, and APOC1 overexpression rescues the phenotype caused by FOXM1 knockdown.","method":"ChIP and luciferase reporter assay for FOXM1-APOC1 promoter interaction; FOXM1/APOC1 knockdown and APOC1 rescue; CCK-8, colony formation, wound healing, transwell assays; flow cytometry for M2 markers; mouse transplant tumor model","journal":"Mutation research","confidence":"Medium","confidence_rationale":"Tier 2 — promoter binding by ChIP + reporter; functional rescue places APOC1 downstream of FOXM1; single lab","pmids":["40139083"],"is_preprint":false},{"year":2025,"finding":"ZKSCAN5 acts as a transcriptional repressor of APOC1 through direct promoter binding; APOC1 inhibits ferroptosis in prostate cancer by modulating cholesterol homeostasis via the PI3K/AKT/SREBP2/SLC1A5 signaling cascade; SREBP2 directly binds the SLC1A5 promoter.","method":"ChIP and Cut&Tag for ZKSCAN5-APOC1 promoter binding and SREBP2-SLC1A5 promoter binding; APOC1 knockdown/overexpression; ferroptosis assays; PI3K/AKT/SREBP2/SLC1A5 pathway western blot; xenograft mouse model","journal":"Journal of translational medicine","confidence":"Medium","confidence_rationale":"Tier 2 — multiple ChIP/Cut&Tag experiments establish transcriptional hierarchy; pathway validated by western blot; single lab","pmids":["41029397"],"is_preprint":false},{"year":2023,"finding":"Knockdown of Apoc1 overcomes sorafenib resistance in esophageal cancer cells by promoting ferroptosis via upregulation of ROS and MDA and downregulation of GSH; this effect is mediated through GPX4, as GPX4 manipulation rescues Apoc1 knockdown-induced ferroptosis.","method":"shRNA lentiviral Apoc1 knockdown; MTT cell viability; ROS/MDA/GSH measurement; GPX4 western blot; erastin and sorafenib treatment; rescue with GPX4 overexpression; xenograft mouse model","journal":"Gene","confidence":"Medium","confidence_rationale":"Tier 2 — GPX4 rescue experiment mechanistically places APOC1 upstream of GPX4 in ferroptosis regulation; in vivo validation; single lab","pmids":["37804922"],"is_preprint":false},{"year":2025,"finding":"APOC1 expressed in macrophages promotes pulmonary metastasis of colorectal cancer by activating STAT3 signaling, which drives CCL2 and CCL5 chemokine secretion; antibodies against CCL2 and CCL5 partially block the pro-metastatic effects of APOC1-expressing macrophages.","method":"APOC1 knockdown in macrophages; co-culture with CRC cells; transwell invasion/migration and EMT assays; ELISA for CCL2 and CCL5; CCL2/CCL5 neutralizing antibody blockade; STAT3 phosphorylation western blot; in vivo pulmonary metastasis mouse model","journal":"International immunopharmacology","confidence":"Medium","confidence_rationale":"Tier 2 — functional epistasis (antibody blockade of downstream chemokines) and STAT3 pathway analysis; in vivo validation; single lab","pmids":["40194454"],"is_preprint":false},{"year":1986,"finding":"APOC1 and APOE genes are tandemly oriented on chromosome 19q and separated by ~6 kb of genomic DNA, with a single lambda phage clone carrying both genes, suggesting possible coordinate regulation of the apolipoprotein gene cluster.","method":"Somatic cell hybrid panel with chromosome 19 long/short arm translocation; Southern blotting with cDNA probes; isolation of overlapping cosmid/lambda phage clones spanning APOC1 and APOE","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1 — direct molecular cloning establishes gene organization; highly cited foundational study","pmids":["3459164"],"is_preprint":false},{"year":1988,"finding":"The HpaI restriction site polymorphism associated with familial dysbetalipoproteinemia is located 317 bp upstream of the APOC1 transcription initiation site in the APOC1 promoter region.","method":"Molecular cloning and DNA sequencing of genomic clones; construction of detailed restriction map of the APOE-APOC1-APOC2 gene cluster by overlapping cosmid analysis","journal":"Biochemical and biophysical research communications","confidence":"High","confidence_rationale":"Tier 1 — direct sequencing and physical mapping; foundational structural study","pmids":["2897845"],"is_preprint":false},{"year":2022,"finding":"In zebrafish, apoc1 expression in microglia is uniquely regulated by RXR receptors and is differentially controlled by LXR/RXR versus PPAR/RXR modulating compounds (LXR/RXR modulation affects apoc1 while PPAR/RXR affects apoeb), establishing a distinct transcriptional regulatory circuit for apoc1 in CNS microglia.","method":"In situ hybridization (HCR) for apoc1 in zebrafish CNS; pharmacological LXR/RXR and PPAR/RXR modulation; RT-qPCR quantification of apoc1 and apoeb transcripts in whole heads and individual microglia","journal":"Biology open","confidence":"Medium","confidence_rationale":"Tier 2 — pharmacological dissection with in situ single-cell quantification; zebrafish ortholog; single lab","pmids":["34878094"],"is_preprint":false}],"current_model":"APOC1 encodes a small exchangeable apolipoprotein that (1) inhibits lipoprotein lipase (LPL)-mediated TG-lipolysis and stimulates hepatic VLDL production, causing hypertriglyceridemia; (2) inhibits cholesteryl ester transfer protein (CETP) activity via HDL-association; (3) activates LCAT; (4) binds phospholipids through C-terminal aromatic residues F42/F46; (5) promotes HCV membrane fusion via direct interaction with the viral surface; and (6) in cancer contexts, drives tumor progression and macrophage M2 polarization through direct binding to STAT3, CD163/CD206, MTCH2, and Clusterin, and by modulating ferroptosis through GPX4 and the PI3K/AKT/SREBP2/SLC1A5 axis, while its transcription is regulated upstream by FOXM1, ZNF460, and ZKSCAN5, and epigenetically by SMYD2/H3K4me3."},"narrative":{"teleology":[{"year":1976,"claim":"Establishing that APOC1 is an activator of LCAT resolved a fundamental question about which apolipoproteins regulate this central enzyme in reverse cholesterol transport.","evidence":"In vitro LCAT activation assay using chemically synthesized full-length 57-residue apoC-I versus native protein","pmids":["179085"],"confidence":"High","gaps":["Structural basis of LCAT activation by apoC-I not determined","Relative contribution of apoC-I vs apoA-I to LCAT activation in vivo not established"]},{"year":1986,"claim":"Mapping APOC1 in tandem with APOE on chromosome 19q established the physical organization of the apolipoprotein gene cluster, raising the possibility of coordinate transcriptional regulation.","evidence":"Somatic cell hybrid panel and overlapping lambda phage/cosmid clones spanning APOC1 and APOE","pmids":["3459164","2897845"],"confidence":"High","gaps":["Coordinate regulatory elements between APOE and APOC1 not functionally tested in this study"]},{"year":2004,"claim":"Demonstrating that apoC-I directly inhibits LPL-mediated triglyceride lipolysis — rather than blocking hepatic receptor-mediated lipoprotein clearance — resolved the principal mechanism of apoC-I-induced hypertriglyceridemia.","evidence":"In vitro LPL lipolysis assay with purified apoC-I; [³H]TG-VLDL clearance in APOC1 transgenic and apoE-deficient × APOC1 transgenic mice with lactoferrin blockade of hepatic clearance","pmids":["15576844"],"confidence":"High","gaps":["Structural basis of LPL inhibition by apoC-I not resolved","Relative quantitative contribution of LPL inhibition vs VLDL overproduction in humans unknown"]},{"year":2005,"claim":"Two independent studies established that APOC1 secretion is post-transcriptionally regulated by intracellular cholesterol and that HDL-associated apoC-I is a potent endogenous CETP inhibitor, linking APOC1 to both metabolic sensing and HDL-cholesterol homeostasis.","evidence":"HepG2 cholesterol/TG loading with paired mRNA and protein measurements; human apoA-I/CETP double-transgenic rat model with CETP activity assay on reconstituted lipoproteins","pmids":["15694932","16282639"],"confidence":"Medium","gaps":["Molecular mechanism of cholesterol-dependent post-transcriptional regulation of apoC-I not identified","Structural determinants of CETP inhibition by apoC-I not defined"]},{"year":2006,"claim":"Graded apoC-I gene dose experiments in apoE-null mice revealed that endogenous apoC-I raises VLDL-TG through two independent mechanisms — stimulating hepatic VLDL production and attenuating LPL activity — quantifying the dual contribution for the first time.","evidence":"apoe−/−apoc1−/−, apoe−/−apoc1+/−, and apoe−/−apoc1+/+ mice with hepatic VLDL-TG/apoB production rates and [³H]TG-VLDL clearance","pmids":["16537968"],"confidence":"High","gaps":["Mechanism by which apoC-I stimulates hepatic VLDL assembly not elucidated"]},{"year":2007,"claim":"Showing that HDL-associated apoC-I directly promotes HCV membrane fusion — dependent on the E2 HVR1 domain — extended APOC1 function beyond lipid metabolism to host–pathogen interaction.","evidence":"HCVcc/HCVpp infectivity, membrane fusion kinetics, binding assays, and HVR1 mutant viruses","pmids":["17761674"],"confidence":"High","gaps":["Precise binding interface between apoC-I and HCV E2 not structurally resolved","In vivo relevance in human HCV infection not directly tested"]},{"year":2008,"claim":"Identification of F42 and F46 in the C-terminal amphipathic helix as critical phospholipid-binding residues provided the first molecular-level understanding of how apoC-I associates with lipoprotein surfaces.","evidence":"Site-directed mutagenesis, DMPC binding Kd, sedimentation velocity AUC, and TEM of discoidal complexes","pmids":["18984910"],"confidence":"High","gaps":["High-resolution structure of apoC-I–lipid complex not available","How lipid binding relates to LPL inhibition or CETP inhibition structurally is unknown"]},{"year":2020,"claim":"Discovery that APOC1 directly binds and activates STAT3 to drive EMT and metastasis in ccRCC — including via exosomal transfer to endothelial cells — established a new oncogenic signaling axis for this apolipoprotein.","evidence":"APOC1 knockdown/overexpression in ccRCC lines; exosome isolation and transfer; STAT3 phosphorylation; DPP-4 inhibitor suppression of metastasis","pmids":["32826950"],"confidence":"Medium","gaps":["Direct APOC1-STAT3 binding interface not mapped","Whether DPP-4 acts on APOC1 directly or indirectly not resolved"]},{"year":2022,"claim":"Multiple studies converged to show that APOC1 in macrophages drives M2 polarization through CD163/CD206 interaction and controls tumor immune microenvironment composition; APOC1 knockout in mice reverses M2 polarization via ferroptosis and enhances anti-tumor immunity.","evidence":"scRNA-seq; co-IP of APOC1 with CD163 and CD206; co-culture assays; APOC1−/− mouse tumor models with immune cell profiling","pmids":["35914680","36108528"],"confidence":"Medium","gaps":["Ferroptosis pathway link in macrophage polarization not fully reconstituted biochemically","Whether APOC1-CD163/CD206 interaction is direct or lipid-mediated not distinguished"]},{"year":2022,"claim":"Identification of ZNF460 as a direct transcriptional activator of APOC1 and LXR/RXR-dependent regulation of apoc1 in zebrafish microglia began to define the transcription factor network controlling APOC1 expression in different cell types.","evidence":"ChIP and luciferase reporter for ZNF460 binding to APOC1 promoter; pharmacological LXR/RXR modulation with in situ hybridization in zebrafish","pmids":["36563923","34878094"],"confidence":"Medium","gaps":["Integration of multiple transcription factors (ZNF460, FOXM1, ZKSCAN5) into a unified regulatory model not achieved","Species-specific differences in transcriptional regulation not resolved"]},{"year":2023,"claim":"A series of studies established that APOC1 suppresses ferroptosis through distinct mechanisms in different cancers — via GPX4 in esophageal cancer and via MTCH2-dependent metabolic rewiring in osteosarcoma — linking APOC1 to cell death resistance and drug sensitivity.","evidence":"GPX4 rescue of APOC1-knockdown-induced ferroptosis; co-IP of APOC1 with MTCH2 and metabolic rescue experiments; sorafenib resistance models","pmids":["37804922","36911382"],"confidence":"Medium","gaps":["Whether APOC1 directly binds GPX4 or acts upstream indirectly is unknown","Unifying mechanism of ferroptosis suppression across cancer types not established"]},{"year":2023,"claim":"Epigenetic activation of APOC1 was shown to occur via lncRNA DLEU1 recruitment of SMYD2 to deposit H3K4me3 at the APOC1 promoter, directly linking epigenetic remodeling to APOC1-driven glycolysis in gastric cancer.","evidence":"RIP and RNA pulldown for DLEU1-SMYD2; ChIP-PCR for SMYD2 and H3K4me3 at APOC1 promoter; glycolytic parameter measurement; xenograft model","pmids":["37478669"],"confidence":"Medium","gaps":["Whether this epigenetic mechanism operates outside gastric cancer is unknown","Relationship between SMYD2-mediated activation and other transcription factors (ZNF460, FOXM1) not tested"]},{"year":2025,"claim":"FOXM1 was identified as a direct transcriptional activator and ZKSCAN5 as a direct repressor of APOC1, while APOC1 was shown to inhibit ferroptosis via PI3K/AKT/SREBP2/SLC1A5 signaling and to drive M2 macrophage polarization via STAT3-CCL2/CCL5 secretion, further detailing the tumor-promoting signaling network downstream of APOC1.","evidence":"ChIP and Cut&Tag for FOXM1 and ZKSCAN5 at APOC1 promoter; ferroptosis assays with PI3K/AKT/SREBP2 pathway inhibition; STAT3 phosphorylation and CCL2/CCL5 neutralizing antibody experiments in macrophage co-cultures; in vivo tumor and metastasis models","pmids":["40139083","41029397","40194454"],"confidence":"Medium","gaps":["No unified model connecting all upstream regulators and downstream effectors","Clinical relevance of APOC1-targeting in cancer therapy not validated in human trials"]},{"year":null,"claim":"The structural basis of APOC1's interactions with STAT3, LPL, CETP, and its multiple cancer-associated partners remains unresolved, and whether APOC1's lipid-binding and oncogenic functions are mechanistically linked or independent is unknown.","evidence":"","pmids":[],"confidence":"Low","gaps":["No high-resolution structure of APOC1 in complex with any protein partner","Whether apoC-I's lipid-bound versus lipid-free state determines its signaling activities is untested","In vivo relevance of APOC1-driven immune reprogramming in human cancer not established"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[2,4]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[0,1,5]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[0,1,3,5,8]}],"pathway":[{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[0,1,2,5]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[9,10,21]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[8,13,19]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[10,20]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[3,15]}],"complexes":[],"partners":["STAT3","CETP","MTCH2","CLU","CD163","CD206","GPX4","USP40"],"other_free_text":[]},"mechanistic_narrative":"APOC1 encodes a small exchangeable apolipoprotein that functions as a central modulator of lipoprotein metabolism by directly inhibiting lipoprotein lipase (LPL)-mediated triglyceride lipolysis, stimulating hepatic VLDL production, activating lecithin:cholesterol acyltransferase (LCAT), and inhibiting cholesteryl ester transfer protein (CETP) activity when associated with HDL [PMID:15576844, PMID:16537968, PMID:179085, PMID:16282639]. Its C-terminal amphipathic α-helix, particularly aromatic residues F42 and F46, mediates phospholipid binding essential for lipoprotein association, and HDL-bound APOC1 promotes hepatitis C virus membrane fusion through interaction with the HCV E2 glycoprotein hypervariable region 1 [PMID:18984910, PMID:17761674]. In cancer contexts, APOC1 directly binds and activates STAT3 to drive epithelial–mesenchymal transition and metastasis, promotes M2 macrophage polarization through interactions with CD163/CD206 and subsequent CCL2/CCL5 chemokine secretion, and suppresses ferroptosis upstream of GPX4 and through the PI3K/AKT/SREBP2/SLC1A5 axis [PMID:32826950, PMID:35914680, PMID:37804922, PMID:41029397]. APOC1 transcription is activated by FOXM1, ZNF460, and the lncRNA DLEU1/SMYD2-H3K4me3 axis, repressed by ZKSCAN5, and post-transcriptionally regulated by intracellular cholesterol levels [PMID:40139083, PMID:36563923, PMID:37478669, PMID:41029397, PMID:15694932]."},"prefetch_data":{"uniprot":{"accession":"P02654","full_name":"Apolipoprotein C-I","aliases":["Apolipoprotein C1"],"length_aa":83,"mass_kda":9.3,"function":"Inhibitor of lipoprotein binding to the low density lipoprotein (LDL) receptor, LDL receptor-related protein, and very low density lipoprotein (VLDL) receptor. Associates with high density lipoproteins (HDL) and the triacylglycerol-rich lipoproteins in the plasma and makes up about 10% of the protein of the VLDL and 2% of that of HDL. Appears to interfere directly with fatty acid uptake and is also the major plasma inhibitor of cholesteryl ester transfer protein (CETP). Binds free fatty acids and reduces their intracellular esterification. Modulates the interaction of APOE with beta-migrating VLDL and inhibits binding of beta-VLDL to the LDL receptor-related protein","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/P02654/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/APOC1","classification":"Not Classified","n_dependent_lines":94,"n_total_lines":1208,"dependency_fraction":0.07781456953642384},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/APOC1","total_profiled":1310},"omim":[{"mim_id":"613230","title":"PEPTIDASE D; PEPD","url":"https://www.omim.org/entry/613230"},{"mim_id":"608083","title":"APOLIPOPROTEIN C-II; APOC2","url":"https://www.omim.org/entry/608083"},{"mim_id":"600745","title":"APOLIPOPROTEIN C-IV; APOC4","url":"https://www.omim.org/entry/600745"},{"mim_id":"160900","title":"MYOTONIC DYSTROPHY 1; DM1","url":"https://www.omim.org/entry/160900"},{"mim_id":"120700","title":"COMPLEMENT COMPONENT 3; C3","url":"https://www.omim.org/entry/120700"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enriched","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"liver","ntpm":18659.9}],"url":"https://www.proteinatlas.org/search/APOC1"},"hgnc":{"alias_symbol":["Apo-CI","ApoC-I","apo-CIB","apoC-IB","APOC1B"],"prev_symbol":[]},"alphafold":{"accession":"P02654","domains":[{"cath_id":"1.20.5","chopping":"32-83","consensus_level":"medium","plddt":75.8737,"start":32,"end":83}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P02654","model_url":"https://alphafold.ebi.ac.uk/files/AF-P02654-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P02654-F1-predicted_aligned_error_v6.png","plddt_mean":70.69},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=APOC1","jax_strain_url":"https://www.jax.org/strain/search?query=APOC1"},"sequence":{"accession":"P02654","fasta_url":"https://rest.uniprot.org/uniprotkb/P02654.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P02654/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P02654"}},"corpus_meta":[{"pmid":"36108528","id":"PMC_36108528","title":"Inhibition of APOC1 promotes the transformation of M2 into M1 macrophages via the ferroptosis pathway and enhances anti-PD1 immunotherapy in hepatocellular carcinoma based on single-cell RNA sequencing.","date":"2022","source":"Redox biology","url":"https://pubmed.ncbi.nlm.nih.gov/36108528","citation_count":248,"is_preprint":false},{"pmid":"15576844","id":"PMC_15576844","title":"Severe hypertriglyceridemia in human APOC1 transgenic mice is caused by apoC-I-induced inhibition of LPL.","date":"2004","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/15576844","citation_count":116,"is_preprint":false},{"pmid":"3459164","id":"PMC_3459164","title":"Regional mapping of human chromosome 19: organization of genes for plasma lipid transport (APOC1, -C2, and -E and LDLR) and the genes C3, PEPD, and GPI.","date":"1986","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/3459164","citation_count":99,"is_preprint":false},{"pmid":"15274118","id":"PMC_15274118","title":"ApoC-I and ApoC-III as potential plasmatic markers to distinguish between ischemic and hemorrhagic stroke.","date":"2004","source":"Proteomics","url":"https://pubmed.ncbi.nlm.nih.gov/15274118","citation_count":92,"is_preprint":false},{"pmid":"22022282","id":"PMC_22022282","title":"A phenomics-based strategy identifies loci on APOC1, BRAP, and PLCG1 associated with metabolic syndrome phenotype domains.","date":"2011","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/22022282","citation_count":80,"is_preprint":false},{"pmid":"17761674","id":"PMC_17761674","title":"The exchangeable apolipoprotein ApoC-I promotes membrane fusion of hepatitis C virus.","date":"2007","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/17761674","citation_count":79,"is_preprint":false},{"pmid":"32826950","id":"PMC_32826950","title":"ApoC1 promotes the metastasis of clear cell renal cell carcinoma via activation of STAT3.","date":"2020","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/32826950","citation_count":69,"is_preprint":false},{"pmid":"35914680","id":"PMC_35914680","title":"Systematic pan-cancer analysis identifies APOC1 as an immunological biomarker which regulates macrophage polarization and promotes tumor metastasis.","date":"2022","source":"Pharmacological research","url":"https://pubmed.ncbi.nlm.nih.gov/35914680","citation_count":67,"is_preprint":false},{"pmid":"31213910","id":"PMC_31213910","title":"Apolipoprotein C1 (APOC1) promotes tumor progression via MAPK signaling pathways in colorectal cancer.","date":"2019","source":"Cancer management and research","url":"https://pubmed.ncbi.nlm.nih.gov/31213910","citation_count":56,"is_preprint":false},{"pmid":"16537968","id":"PMC_16537968","title":"Endogenous apoC-I increases hyperlipidemia in apoE-knockout mice by stimulating VLDL production and inhibiting LPL.","date":"2006","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/16537968","citation_count":47,"is_preprint":false},{"pmid":"15681655","id":"PMC_15681655","title":"Kinetic stabilization and fusion of apolipoprotein A-2:DMPC disks: comparison with apoA-1 and apoC-1.","date":"2005","source":"Biophysical journal","url":"https://pubmed.ncbi.nlm.nih.gov/15681655","citation_count":43,"is_preprint":false},{"pmid":"15364690","id":"PMC_15364690","title":"APOE and APOC1 promoter polymorphisms and the risk of Alzheimer disease in African American and Caribbean Hispanic individuals.","date":"2004","source":"Archives of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/15364690","citation_count":41,"is_preprint":false},{"pmid":"179085","id":"PMC_179085","title":"The solid phase synthesis of a protein activator for lecithin-cholesterol acyltransferase corresponding to human plasma apoC-I.","date":"1976","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/179085","citation_count":36,"is_preprint":false},{"pmid":"11825674","id":"PMC_11825674","title":"Genetic association of an apolipoprotein C-I (APOC1) gene polymorphism with late-onset Alzheimer's disease.","date":"2002","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/11825674","citation_count":35,"is_preprint":false},{"pmid":"12364552","id":"PMC_12364552","title":"Plasma kinetics of VLDL and HDL apoC-I in normolipidemic and hypertriglyceridemic subjects.","date":"2002","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/12364552","citation_count":35,"is_preprint":false},{"pmid":"30443289","id":"PMC_30443289","title":"Biothiols and oxidative stress markers and polymorphisms of TOMM40 and APOC1 genes in Alzheimer's disease patients.","date":"2018","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/30443289","citation_count":32,"is_preprint":false},{"pmid":"12867543","id":"PMC_12867543","title":"Plasma turnover of HDL apoC-I, apoC-III, and apoE in humans: in vivo evidence for a link between HDL apoC-III and apoA-I metabolism.","date":"2003","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/12867543","citation_count":32,"is_preprint":false},{"pmid":"2897845","id":"PMC_2897845","title":"Exact localization of the familial dysbetalipoproteinemia associated HpaI restriction site in the promoter region of the APOC1 gene.","date":"1988","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/2897845","citation_count":29,"is_preprint":false},{"pmid":"3013172","id":"PMC_3013172","title":"There are two gene sequences for human apolipoprotein CI (apo CI) on chromosome 19, one of which is 4 kb from the gene for apo E.","date":"1986","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/3013172","citation_count":29,"is_preprint":false},{"pmid":"25206869","id":"PMC_25206869","title":"APOE and APOC1 gene polymorphisms are associated with cognitive impairment progression in Chinese patients with late-onset Alzheimer's disease.","date":"2014","source":"Neural regeneration research","url":"https://pubmed.ncbi.nlm.nih.gov/25206869","citation_count":28,"is_preprint":false},{"pmid":"15514255","id":"PMC_15514255","title":"Synthesis and secretion of apoC-I and apoE during maturation of human SW872 liposarcoma cells.","date":"2004","source":"The Journal of nutrition","url":"https://pubmed.ncbi.nlm.nih.gov/15514255","citation_count":28,"is_preprint":false},{"pmid":"21533863","id":"PMC_21533863","title":"Genetic influences on Alzheimer's disease: evidence of interactions between the genes APOE, APOC1 and ACE in a sample population from the South of Brazil.","date":"2011","source":"Neurochemical research","url":"https://pubmed.ncbi.nlm.nih.gov/21533863","citation_count":24,"is_preprint":false},{"pmid":"12860251","id":"PMC_12860251","title":"Plasma concentration and lipoprotein distribution of ApoC-I is dependent on ApoE genotype rather than the Hpa I ApoC-I promoter polymorphism.","date":"2003","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/12860251","citation_count":23,"is_preprint":false},{"pmid":"28018301","id":"PMC_28018301","title":"Screening and Identification of APOC1 as a Novel Potential Biomarker for Differentiate of Mycoplasma pneumoniae in Children.","date":"2016","source":"Frontiers in microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/28018301","citation_count":21,"is_preprint":false},{"pmid":"36563923","id":"PMC_36563923","title":"ZNF460 mediates epithelial-mesenchymal transition to promote gastric cancer progression by transactivating APOC1 expression.","date":"2022","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/36563923","citation_count":20,"is_preprint":false},{"pmid":"37541400","id":"PMC_37541400","title":"Huanglian Ganjiang decoction alleviates ulcerative colitis by restoring gut barrier via APOC1-JNK/P38 MAPK signal pathway based on proteomic analysis.","date":"2023","source":"Journal of ethnopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/37541400","citation_count":20,"is_preprint":false},{"pmid":"37668862","id":"PMC_37668862","title":"Nanoparticle (NP)-mediated APOC1 silencing to inhibit MAPK/ERK and NF-κB pathway and suppress breast cancer growth and metastasis.","date":"2023","source":"Science China. Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/37668862","citation_count":20,"is_preprint":false},{"pmid":"11714102","id":"PMC_11714102","title":"APOE and APOC1 genetic polymorphisms in age-associated memory impairment.","date":"2001","source":"Neurogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/11714102","citation_count":14,"is_preprint":false},{"pmid":"29636060","id":"PMC_29636060","title":"Effects of apoC1 genotypes on the hormonal levels, metabolic profile and PAF-AH activity in Chinese women with polycystic ovary syndrome.","date":"2018","source":"Lipids in health and disease","url":"https://pubmed.ncbi.nlm.nih.gov/29636060","citation_count":14,"is_preprint":false},{"pmid":"36911382","id":"PMC_36911382","title":"APOC1 promotes the progression of osteosarcoma by binding to MTCH2.","date":"2023","source":"Experimental and therapeutic medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36911382","citation_count":14,"is_preprint":false},{"pmid":"15777558","id":"PMC_15777558","title":"The common insertional polymorphism in the APOC1 promoter is associated with serum apolipoprotein C-I levels in Hispanic children.","date":"2004","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/15777558","citation_count":14,"is_preprint":false},{"pmid":"18958591","id":"PMC_18958591","title":"Molecular cloning and expression characterization of ApoC-I in the orange-spotted grouper.","date":"2008","source":"Fish physiology and biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18958591","citation_count":14,"is_preprint":false},{"pmid":"37478669","id":"PMC_37478669","title":"Long noncoding RNA DLEU1 promotes proliferation and glycolysis of gastric cancer cells via APOC1 upregulation by recruiting SMYD2 to induce trimethylation of H3K4 modification.","date":"2023","source":"Translational oncology","url":"https://pubmed.ncbi.nlm.nih.gov/37478669","citation_count":13,"is_preprint":false},{"pmid":"37305534","id":"PMC_37305534","title":"APOC1 exacerbates renal fibrosis through the activation of the NF-κB signaling pathway in IgAN.","date":"2023","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/37305534","citation_count":13,"is_preprint":false},{"pmid":"20209111","id":"PMC_20209111","title":"Detection of two distinct forms of apoC-I in great apes.","date":"2010","source":"Comparative biochemistry and physiology. Part D, Genomics & proteomics","url":"https://pubmed.ncbi.nlm.nih.gov/20209111","citation_count":13,"is_preprint":false},{"pmid":"26689228","id":"PMC_26689228","title":"Lactobacillus plantarum NCIMB8826 ameliorates inflammation of colon and skin in human APOC1 transgenic mice.","date":"2015","source":"Beneficial microbes","url":"https://pubmed.ncbi.nlm.nih.gov/26689228","citation_count":12,"is_preprint":false},{"pmid":"38241194","id":"PMC_38241194","title":"APOC1 reduced anti-PD-1 immunotherapy of nonsmall cell lung cancer via the transformation of M2 into M1 macrophages by ferroptosis by NRF2/HO-1.","date":"2024","source":"Anti-cancer drugs","url":"https://pubmed.ncbi.nlm.nih.gov/38241194","citation_count":12,"is_preprint":false},{"pmid":"18984910","id":"PMC_18984910","title":"Aromatic residues in the C-terminal helix of human apoC-I mediate phospholipid interactions and particle morphology.","date":"2008","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/18984910","citation_count":12,"is_preprint":false},{"pmid":"19252179","id":"PMC_19252179","title":"ApoE and ApoC-I polymorphisms: association of genotype with cardiovascular disease phenotype in African Americans.","date":"2009","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/19252179","citation_count":11,"is_preprint":false},{"pmid":"23354389","id":"PMC_23354389","title":"Human HDL containing a novel apoC-I isoform induces smooth muscle cell apoptosis.","date":"2013","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/23354389","citation_count":11,"is_preprint":false},{"pmid":"39041949","id":"PMC_39041949","title":"M2 macrophage exosome-derived Apoc1 promotes ferroptosis resistance in osteosarcoma by inhibiting ACSF2 deubiquitination.","date":"2024","source":"Molecular carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/39041949","citation_count":10,"is_preprint":false},{"pmid":"34878094","id":"PMC_34878094","title":"Modulation of retinoid-X-receptors differentially regulates expression of apolipoprotein genes apoc1 and apoeb by zebrafish microglia.","date":"2022","source":"Biology open","url":"https://pubmed.ncbi.nlm.nih.gov/34878094","citation_count":10,"is_preprint":false},{"pmid":"37804922","id":"PMC_37804922","title":"Inhibition of Apoc1 reverses resistance of sorafenib by promoting ferroptosis in esophageal cancers.","date":"2023","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/37804922","citation_count":10,"is_preprint":false},{"pmid":"2410524","id":"PMC_2410524","title":"Monoclonal antibodies to rat C apolipoproteins: production and characterization of a unique antibody whose binding to apoC-I is inhibited by nonionic detergents.","date":"1985","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/2410524","citation_count":10,"is_preprint":false},{"pmid":"38646507","id":"PMC_38646507","title":"Shared genetic aetiology of Alzheimer's disease and age-related macular degeneration by APOC1 and APOE genes.","date":"2024","source":"BMJ neurology open","url":"https://pubmed.ncbi.nlm.nih.gov/38646507","citation_count":9,"is_preprint":false},{"pmid":"2881271","id":"PMC_2881271","title":"Human apolipoprotein CI (ApoC1) gene locus: BglI dimorphic site.","date":"1987","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/2881271","citation_count":9,"is_preprint":false},{"pmid":"36891052","id":"PMC_36891052","title":"APOC1 as a novel diagnostic biomarker for DN based on machine learning algorithms and experiment.","date":"2023","source":"Frontiers in endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/36891052","citation_count":8,"is_preprint":false},{"pmid":"35695660","id":"PMC_35695660","title":"Apolipoprotein C1 (APOC1), A Candidate Diagnostic Serum Biomarker for Breast Cancer Identified by Serum Proteomics Study.","date":"2022","source":"Critical reviews in eukaryotic gene expression","url":"https://pubmed.ncbi.nlm.nih.gov/35695660","citation_count":7,"is_preprint":false},{"pmid":"31006040","id":"PMC_31006040","title":"Assessment of ApoC1, LuzP6, C12orf75 and OCC-1 in cystic glioblastoma using MALDI-TOF mass spectrometry, immunohistochemistry and qRT-PCR.","date":"2019","source":"Medical molecular morphology","url":"https://pubmed.ncbi.nlm.nih.gov/31006040","citation_count":7,"is_preprint":false},{"pmid":"39511608","id":"PMC_39511608","title":"HOXD9/APOC1 axis promotes macrophage M1 polarization to exacerbate diabetic kidney disease progression through activating NF-κB signaling pathway.","date":"2024","source":"Hereditas","url":"https://pubmed.ncbi.nlm.nih.gov/39511608","citation_count":6,"is_preprint":false},{"pmid":"15694932","id":"PMC_15694932","title":"Post-transcriptional regulation of apoC-I synthesis and secretion in human HepG2 cells.","date":"2005","source":"Atherosclerosis","url":"https://pubmed.ncbi.nlm.nih.gov/15694932","citation_count":6,"is_preprint":false},{"pmid":"21090","id":"PMC_21090","title":"Ionization behaviour of native apolipoproteins and of their complexes with lecithin. 2. Potentiometric titration of the native apo-A-II, apoC-I, apoC-III proteins and of their complexes with dimyristoyl lecithin.","date":"1977","source":"European journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21090","citation_count":6,"is_preprint":false},{"pmid":"2442277","id":"PMC_2442277","title":"Expression of a monoclonal antibody-defined aminoterminal epitope of human apoC-I on native and reconstituted lipoproteins.","date":"1987","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/2442277","citation_count":6,"is_preprint":false},{"pmid":"16282639","id":"PMC_16282639","title":"Human apoA-I expression in CETP transgenic rats leads to lower levels of apoC-I in HDL and to magnification of CETP-mediated lipoprotein changes.","date":"2005","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/16282639","citation_count":6,"is_preprint":false},{"pmid":"38172247","id":"PMC_38172247","title":"miR-378a-5p exerts tumor-suppressive effects on esophageal squamous cell carcinoma after neoadjuvant immunotherapy by downregulating APOC1/CEP55.","date":"2024","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/38172247","citation_count":5,"is_preprint":false},{"pmid":"12112572","id":"PMC_12112572","title":"Lipoprotein lipase and APOE/APOC-I/APOC-II gene cluster diversity in native Brazilian populations.","date":"2002","source":"American journal of human biology : the official journal of the Human Biology Council","url":"https://pubmed.ncbi.nlm.nih.gov/12112572","citation_count":5,"is_preprint":false},{"pmid":"36302088","id":"PMC_36302088","title":"ApoC1 promotes glioma metastasis by enhancing epithelial-mesenchymal transition and activating the STAT3 pathway.","date":"2022","source":"Neurological research","url":"https://pubmed.ncbi.nlm.nih.gov/36302088","citation_count":4,"is_preprint":false},{"pmid":"35149606","id":"PMC_35149606","title":"Genetic Variants and Haplotypes of TOMM40, APOE, and APOC1 are Related to the Age of Onset of Late-onset Alzheimer Disease in a Colombian Population.","date":"2022","source":"Alzheimer disease and associated disorders","url":"https://pubmed.ncbi.nlm.nih.gov/35149606","citation_count":4,"is_preprint":false},{"pmid":"36216850","id":"PMC_36216850","title":"Feasibility of ApoC1 serum levels as tumor biomarker in glioblastoma patients: a pilot study.","date":"2022","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/36216850","citation_count":4,"is_preprint":false},{"pmid":"3928790","id":"PMC_3928790","title":"Monoclonal antibody to rat apoC: multiple binding to apoC-I on lipoproteins increases its affinity constant.","date":"1985","source":"Journal of lipid research","url":"https://pubmed.ncbi.nlm.nih.gov/3928790","citation_count":4,"is_preprint":false},{"pmid":"37743383","id":"PMC_37743383","title":"Serum APOC1 levels are decreased in young autoantibody positive children who rapidly progress to type 1 diabetes.","date":"2023","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/37743383","citation_count":4,"is_preprint":false},{"pmid":"37981873","id":"PMC_37981873","title":"miRNA-660-3p inhibits malignancy in glioblastoma via negative regulation of APOC1-TGFβ2 signaling pathway.","date":"2023","source":"Cancer biology & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/37981873","citation_count":3,"is_preprint":false},{"pmid":"39901699","id":"PMC_39901699","title":"ALYREF-Mediated Regulation of TBL1XR1 and KMT2E Synergistically Upregulates APOC1, Contributing to Oxaliplatin Resistance in Esophageal Cancer.","date":"2025","source":"Cancer research and treatment","url":"https://pubmed.ncbi.nlm.nih.gov/39901699","citation_count":3,"is_preprint":false},{"pmid":"39873475","id":"PMC_39873475","title":"APOC1 knockdown induces apoptosis and decreases angiogenesis in diffuse large B-cell lymphoma cells through blocking the PI3K/AKT/mTOR pathway.","date":"2025","source":"Biomolecules & biomedicine","url":"https://pubmed.ncbi.nlm.nih.gov/39873475","citation_count":3,"is_preprint":false},{"pmid":"39395990","id":"PMC_39395990","title":"PHACTR1 and APOC1 genetic variants are associated with multi-vessel coronary artery disease.","date":"2024","source":"Lipids in health and disease","url":"https://pubmed.ncbi.nlm.nih.gov/39395990","citation_count":2,"is_preprint":false},{"pmid":"38912305","id":"PMC_38912305","title":"TOMM40 and APOC1 variants differentiate the impacts of the APOE ε4 allele on Alzheimer's disease risk across sexes, ages, and ancestries.","date":"2024","source":"Alzheimer's & dementia (Amsterdam, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/38912305","citation_count":2,"is_preprint":false},{"pmid":"39630345","id":"PMC_39630345","title":"Apoc1 Knockdown Alleviates High Glucose-induced Oxidative Stress and Apoptosis of Renal Tubular Cells by Binding to Clusterin.","date":"2024","source":"Cell biochemistry and biophysics","url":"https://pubmed.ncbi.nlm.nih.gov/39630345","citation_count":2,"is_preprint":false},{"pmid":"40194454","id":"PMC_40194454","title":"APOC1 expressed in macrophages promotes the pulmonary metastasis of colorectal cancer via CCL2/CCL5.","date":"2025","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/40194454","citation_count":2,"is_preprint":false},{"pmid":"33970751","id":"PMC_33970751","title":"Analysis of whole genome sequenced cases and controls shows that the association of variants in TOMM40, BCAM, NECTIN2 and APOC1 with late onset Alzheimer's disease is driven by linkage disequilibrium with APOE ε2/ε3/ε4 alleles.","date":"2021","source":"Journal of neurogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/33970751","citation_count":2,"is_preprint":false},{"pmid":"36101402","id":"PMC_36101402","title":"The Mean ApoC1 Serum Level in Postoperative Samples from Neurosurgical Patients Is Lower than in Preoperative Samples and during Chemotherapy.","date":"2022","source":"Biology","url":"https://pubmed.ncbi.nlm.nih.gov/36101402","citation_count":2,"is_preprint":false},{"pmid":"25160599","id":"PMC_25160599","title":"Higher primates, but not New World monkeys, have a duplicate set of enhancers flanking their apoC-I genes.","date":"2014","source":"Comparative biochemistry and physiology. Part D, Genomics & proteomics","url":"https://pubmed.ncbi.nlm.nih.gov/25160599","citation_count":2,"is_preprint":false},{"pmid":"41029397","id":"PMC_41029397","title":"ZKSCAN5 transcriptional regulation of APOC1 modulates ferroptosis via PI3K/AKT/SREBP2/SLC1A5 axis.","date":"2025","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/41029397","citation_count":1,"is_preprint":false},{"pmid":"41053280","id":"PMC_41053280","title":"Transcriptome analysis combined with single-cell analysis identified that APOC1 influences cholesterol transport by macrophages in ccRCC.","date":"2025","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/41053280","citation_count":1,"is_preprint":false},{"pmid":"40349270","id":"PMC_40349270","title":"The roles, signalling pathways and therapeutic implications of Apoc1 in cancer.","date":"2025","source":"Discover oncology","url":"https://pubmed.ncbi.nlm.nih.gov/40349270","citation_count":1,"is_preprint":false},{"pmid":"37328602","id":"PMC_37328602","title":"Protective Association of APOC1/rs4420638 with Risk of Obesity: A case-control Study in Portuguese Children.","date":"2023","source":"Biochemical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/37328602","citation_count":1,"is_preprint":false},{"pmid":"38771126","id":"PMC_38771126","title":"Shexiang tongxin dropping pill alleviates myocardial injury induced by coronary microembolization by down-regulating APOC1 to inhibit STAT3 signaling pathway.","date":"2024","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/38771126","citation_count":1,"is_preprint":false},{"pmid":"39330494","id":"PMC_39330494","title":"The Endogenous Inhibitor of CETP, apoC1, Remains Ineffective In Vivo after Correction of Hyperglycemia in People with Type 1 Diabetes.","date":"2024","source":"Metabolites","url":"https://pubmed.ncbi.nlm.nih.gov/39330494","citation_count":1,"is_preprint":false},{"pmid":"28757862","id":"PMC_28757862","title":"Proteogenomic Review of the Changes in Primate apoC-I during Evolution.","date":"2013","source":"Frontiers in biology","url":"https://pubmed.ncbi.nlm.nih.gov/28757862","citation_count":1,"is_preprint":false},{"pmid":"40139083","id":"PMC_40139083","title":"APOC1, transcriptionally regulated by FOXM1, promotes M2 macrophage polarization and cervical cancer progression.","date":"2025","source":"Mutation research","url":"https://pubmed.ncbi.nlm.nih.gov/40139083","citation_count":0,"is_preprint":false},{"pmid":"41408238","id":"PMC_41408238","title":"Role of APOC1 and NOP16 in the diagnosis of prostate cancer.","date":"2025","source":"BMC urology","url":"https://pubmed.ncbi.nlm.nih.gov/41408238","citation_count":0,"is_preprint":false},{"pmid":"40369256","id":"PMC_40369256","title":"Association of APOC1 with cortical atrophy during conversion to Alzheimer's disease.","date":"2025","source":"GeroScience","url":"https://pubmed.ncbi.nlm.nih.gov/40369256","citation_count":0,"is_preprint":false},{"pmid":"32619263","id":"PMC_32619263","title":"[Analysis of rs4420638A/G and -317H1/H2 polymorphisms of APOC1 gene among Chinese patients with pre-eclampsia].","date":"2020","source":"Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/32619263","citation_count":0,"is_preprint":false},{"pmid":"40064358","id":"PMC_40064358","title":"Integrated analysis of single-cell and bulk RNA sequencing identifies APOC1 as a biomarker and therapeutic target for G0/G1 cell cycle arrest in cholangiocarcinoma.","date":"2025","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/40064358","citation_count":0,"is_preprint":false},{"pmid":"39817465","id":"PMC_39817465","title":"APOC1 inhibit NKTCL doxorubicin sensitivity by promoting mitophagy.","date":"2025","source":"IUBMB life","url":"https://pubmed.ncbi.nlm.nih.gov/39817465","citation_count":0,"is_preprint":false},{"pmid":"41623496","id":"PMC_41623496","title":"LAR1 promotes breast carcinogenesis by activating NF-κB signaling pathway through binding and enhancing APOC1 expression.","date":"2025","source":"iScience","url":"https://pubmed.ncbi.nlm.nih.gov/41623496","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.09.30.25336984","title":"Maternal and offspring genome-wide association study of C-reactive protein reveals limited polygenic association with gestational diabetes mellitus","date":"2025-10-02","source":"bioRxiv","url":"https://doi.org/10.1101/2025.09.30.25336984","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.11.29.691286","title":"Protein Compositional Ratio Representation (PCRR) Systematically Improves Human Disease Prediction","date":"2025-12-01","source":"bioRxiv","url":"https://doi.org/10.1101/2025.11.29.691286","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.09.01.25334224","title":"The genetic architecture of postoperative delirium after major surgery and its relationship with non-postoperative neurocognitive conditions","date":"2025-09-02","source":"bioRxiv","url":"https://doi.org/10.1101/2025.09.01.25334224","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.06.10.25329388","title":"Phenome-wide Mendelian randomization identifying circulating proteins for cardiovascular traits in populations of African ancestry","date":"2025-06-11","source":"bioRxiv","url":"https://doi.org/10.1101/2025.06.10.25329388","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.07.01.662592","title":"Haplotype-Resolved DNA Methylation at the<i>APOE</i>Locus identifies Allele-Specific Epigenetic Signatures Relevant to Alzheimer’s Disease Risk","date":"2025-07-02","source":"bioRxiv","url":"https://doi.org/10.1101/2025.07.01.662592","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.05.24.655950","title":"Robust Serum Proteomic Signatures of APOE2","date":"2025-05-29","source":"bioRxiv","url":"https://doi.org/10.1101/2025.05.24.655950","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.01.02.25319880","title":"Integrating GWAS and Transcriptomic Data Using PrediXcan and Multimodal Deep Learning Reveals Genetic Basis and Drug Repositioning Opportunities for Alzheimer’s Disease","date":"2025-01-02","source":"bioRxiv","url":"https://doi.org/10.1101/2025.01.02.25319880","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.08.26.24312584","title":"Large-scale genome-wide analyses with proteomics integration reveal novel loci and biological insights into frailty","date":"2024-08-26","source":"bioRxiv","url":"https://doi.org/10.1101/2024.08.26.24312584","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":50679,"output_tokens":6546,"usd":0.125113},"stage2":{"model":"claude-opus-4-6","input_tokens":10140,"output_tokens":3722,"usd":0.215625},"total_usd":0.340738,"stage1_batch_id":"msgbatch_01TqNM6p6FsoMBT2jzQTwKBr","stage2_batch_id":"msgbatch_01Ya473eco8sTHbvRymQaU8o","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2004,\n      \"finding\": \"ApoC-I directly inhibits LPL-mediated TG-lipolysis in a dose-dependent manner in vitro, and increases plasma half-life of VLDL-TG particles in vivo; this LPL inhibition (not blockade of apoE-mediated hepatic lipoprotein receptors) is the principal mechanism by which apoC-I causes hypertriglyceridemia in APOC1 transgenic mice.\",\n      \"method\": \"In vitro LPL lipolysis assay with purified apoC-I; [3H]TG-VLDL particle clearance in vivo in APOC1 transgenic and apoE-deficient × APOC1 transgenic mice; lactoferrin-treatment to block hepatic clearance\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstituted LPL inhibition assay plus multiple in vivo mouse models with orthogonal readouts; replicated conceptually in a second study (PMID:16537968)\",\n      \"pmids\": [\"15576844\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Endogenous apoC-I (at physiological levels) increases VLDL-TG and VLDL-cholesterol by two independent mechanisms: stimulating hepatic VLDL production and attenuating LPL lipolytic activity, as demonstrated in apoE-knockout mice with graded apoC-I gene doses.\",\n      \"method\": \"Comparison of apoe-/-apoc1-/-, apoe-/-apoc1+/-, and apoe-/-apoc1+/+ mice; hepatic VLDL-TG and VLDL-apoB production rates; [3H]TG-VLDL clearance by white adipose tissue; total postheparin plasma LPL activity\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean genetic dose-response KO model with multiple orthogonal metabolic readouts; extends and confirms PMID:15576844\",\n      \"pmids\": [\"16537968\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1976,\n      \"finding\": \"Synthetic apoC-I corresponding to the full 57-amino acid sequence activates lecithin:cholesterol acyltransferase (LCAT) to the same extent as native apoC-I, establishing apoC-I as an activator of LCAT.\",\n      \"method\": \"Solid-phase peptide synthesis of full-length apoC-I; LCAT activation assay comparing synthetic vs. native protein; lipid-binding studies with DMPC by ultracentrifugation\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution with synthetic protein and direct enzymatic assay\",\n      \"pmids\": [\"179085\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"ApoC-I, when residing in HDL, promotes membrane fusion of HCV with target cells via direct interaction with the HCV surface; this enhancement requires the hypervariable region 1 (HVR1) of HCV E2 glycoprotein, and excess lipid-free apoC-I instead disrupts the viral membrane and abolishes infectivity.\",\n      \"method\": \"HCVcc and HCVpp infectivity assays; membrane fusion rate measurements; binding assays between apoC-I and HCV surface; HVR1 mutant viruses; lipid-free apoC-I dose-response experiments\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal functional assays (fusion rates, infectivity, binding, mutant analysis) in a single study\",\n      \"pmids\": [\"17761674\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"The C-terminal amphipathic α-helix of apoC-I (residues 38–51) contains the major lipid-binding determinants; aromatic residues F42 and F46 are critical for phospholipid (DMPC) binding affinity and for formation of correctly shaped discoidal lipid-protein complexes.\",\n      \"method\": \"LC-MS/MS proteolysis protection assay; site-directed mutagenesis of F42 and F46 to Ala or Gly; DMPC binding affinity by Kd(app); sedimentation velocity analytical ultracentrifugation; transmission electron microscopy of discoidal complexes\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — mutagenesis combined with in vitro binding assays and structural characterization (TEM, AUC) in one study\",\n      \"pmids\": [\"18984910\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"ApoC-I present in HDL constitutes a potent endogenous inhibitor of cholesteryl ester transfer protein (CETP); removal of rat apoC-I from HDL upon human apoA-I overexpression accounts for approximately two-thirds of the loss of CETP-inhibitory activity of HDL.\",\n      \"method\": \"Human apoA-I/CETP double-transgenic rat model; quantification of apoC-I in HDL; CETP activity assay with reconstituted lipoproteins; comparison of CETP inhibition between wild-type and transgenic HDL\",\n      \"journal\": \"Journal of lipid research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo genetic model with direct CETP activity measurement, but single-lab study\",\n      \"pmids\": [\"16282639\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"ApoC-I secretion by human HepG2 hepatocytes is regulated post-transcriptionally by cellular cholesterol levels: increasing cellular cholesterol (via HDL/LDL loading) increases apoC-I secretion without changing apoC-I mRNA; statin-mediated cholesterol depletion reduces secretion; triglyceride loading decreases apoC-I secretion also without mRNA changes.\",\n      \"method\": \"HepG2 cell culture with varied lipid conditions (human serum, LPDS, Intralipid, cholesterol loading, statin treatment); apoC-I and apoE protein measured in cell lysates and media by ELISA; apoC-I mRNA by Northern/RT-PCR\",\n      \"journal\": \"Atherosclerosis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal conditions in cell culture with paired mRNA and protein measurement, single lab\",\n      \"pmids\": [\"15694932\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"In maturing human SW872 liposarcoma (adipocyte-like) cells, increased intracellular cholesterol and triglyceride accumulation drives increased apoC-I and apoE secretion independently of extracellular lipids; long-term insulin treatment inhibits apoC-I secretion; apoC-I and apoE are differentially regulated at the transcriptional level.\",\n      \"method\": \"SW872 cell differentiation assay; apoC-I and apoE protein measured in cell lysates and media; cellular lipid quantification; insulin treatment; lipoprotein-deficient serum conditions; mRNA measurement\",\n      \"journal\": \"The Journal of nutrition\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple conditions with paired protein/mRNA readouts; single lab\",\n      \"pmids\": [\"15514255\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ApoC1 promotes metastasis of clear cell renal cell carcinoma (ccRCC) cells by activating the STAT3 signaling pathway and inducing EMT; ApoC1 packaged in tumor cell exosomes is transferred to vascular endothelial cells, where it also activates STAT3 to enhance metastasis; DPP-4 inhibition suppresses ApoC1-driven metastasis.\",\n      \"method\": \"ApoC1 knockdown/overexpression in ccRCC cell lines; transwell invasion/migration assays; EMT marker western blot; exosome isolation and transfer experiments; STAT3 phosphorylation western blot; DPP-4 inhibitor treatment\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple functional assays (invasion, EMT, exosome transfer, STAT3 activation) in single lab\",\n      \"pmids\": [\"32826950\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"APOC1 promotes M2 macrophage polarization through interaction with CD163 and CD206; macrophages overexpressing APOC1 drive ccRCC metastasis by secreting CCL5; co-culture of RCC cells with macrophages induces TAM generation with M2 phenotype, which is blocked by APOC1 silencing.\",\n      \"method\": \"Single-cell RNA sequencing; APOC1 silencing in macrophages; co-culture of RCC cells with macrophages; CCL5 ELISA; co-immunoprecipitation of APOC1 with CD163 and CD206\",\n      \"journal\": \"Pharmacological research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — co-IP identifies binding partners, functional assays confirm polarization and CCL5 secretion; single lab\",\n      \"pmids\": [\"35914680\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Inhibition of APOC1 reverses M2-to-M1 macrophage polarization via the ferroptosis pathway in tumor-associated macrophages from HCC; APOC1-/- mice show reduced tumor growth with increased CD8+ T cells and M1 macrophages and decreased M2 macrophages.\",\n      \"method\": \"scRNA-seq; APOC1-/- C57BL/6 mouse tumor model; mass spectrometry immune cell profiling; ferroptosis pathway analysis\",\n      \"journal\": \"Redox biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo genetic KO model plus single-cell transcriptomics, but mechanistic link to ferroptosis not fully reconstituted\",\n      \"pmids\": [\"36108528\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"APOC1 interacts directly with MTCH2 (mitochondrial carrier homolog 2) in osteosarcoma cells; APOC1 knockdown elevates oxidative phosphorylation and decreases the Warburg effect, and MTCH2 overexpression rescues these metabolic effects, placing APOC1 upstream of MTCH2 in the control of cancer cell metabolism.\",\n      \"method\": \"Co-immunoprecipitation of APOC1 with MTCH2; APOC1 siRNA knockdown; CCK-8 and TUNEL apoptosis assays; Warburg effect measurement (extracellular lactate, OCR); rescue experiments with MTCH2 overexpression\",\n      \"journal\": \"Experimental and therapeutic medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — co-IP confirms interaction; metabolic rescue experiments establish functional hierarchy; single lab\",\n      \"pmids\": [\"36911382\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"M2 macrophage exosome-derived Apoc1 promotes ferroptosis resistance in osteosarcoma by inhibiting the interaction of USP40 deubiquitinase with ACSF2, thereby increasing ACSF2 ubiquitination and proteasomal degradation.\",\n      \"method\": \"M2 macrophage exosome isolation and co-culture with OS cells; shApoc1 knockdown; erastin ferroptosis induction; co-immunoprecipitation of Apoc1, ACSF2, and USP40; proteasomal inhibitor MG132; cyclohexanone protein synthesis inhibition\",\n      \"journal\": \"Molecular carcinogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — co-IP with multiple partners and functional rescue experiments; single lab\",\n      \"pmids\": [\"39041949\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"APOC1 binds directly to STAT3 in cardiomyocytes and increases phospho-STAT3 (p-STAT3) in the nucleus, activating the STAT3 signaling pathway to promote inflammation and apoptosis in coronary microembolization-induced myocardial injury.\",\n      \"method\": \"Co-immunoprecipitation of APOC1 with STAT3; immunofluorescence for p-STAT3 subcellular localization; western blot for pathway proteins; LPS-treated primary cardiomyocyte model; APOC1 overexpression rescue of STDP effects\",\n      \"journal\": \"Aging\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — co-IP demonstrates direct APOC1-STAT3 binding; functional consequence shown in cell model; single lab\",\n      \"pmids\": [\"38771126\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Apoc1 knockdown in renal tubular epithelial cells alleviates high-glucose-induced oxidative stress and apoptosis by binding to and regulating Clusterin; Clusterin silencing blocks the protective effects of Apoc1 knockdown, placing Apoc1-Clusterin interaction as the mechanistic axis.\",\n      \"method\": \"Co-immunoprecipitation of Apoc1 with Clusterin in HK-2 cells; CCK-8 viability; DCFH-DA ROS staining; MDA/SOD assays; TUNEL apoptosis; western blot; DN mouse model with immunofluorescence\",\n      \"journal\": \"Cell biochemistry and biophysics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — co-IP confirms binding; functional rescue/epistasis by dual KD; single lab\",\n      \"pmids\": [\"39630345\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"APOC1 silencing suppresses breast cancer growth and metastasis by inhibiting the MAPK/ERK kinase pathway and restraining NF-κB-driven transcription of pro-metastatic target genes; nanoparticle-delivered siAPOC1 recapitulates these effects in orthotopic and liver metastasis mouse models.\",\n      \"method\": \"APOC1 siRNA knockdown in breast cancer cell lines; western blot for ERK/MAPK and NF-κB pathway proteins; in vitro invasion/migration assays; GSH-responsive NP-siAPOC1 in orthotopic and liver metastasis mouse models\",\n      \"journal\": \"Science China. Life sciences\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vitro pathway analysis combined with in vivo mouse model; single lab\",\n      \"pmids\": [\"37668862\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"The lncRNA DLEU1 recruits the histone methyltransferase SMYD2 to the APOC1 promoter, inducing H3K4me3 modification and thereby upregulating APOC1 transcription, which in turn promotes gastric cancer cell proliferation and glycolysis.\",\n      \"method\": \"RIP and RNA pulldown (DLEU1-SMYD2 interaction); ChIP-PCR (SMYD2 binding to APOC1 promoter and H3K4me3 modification); ectopic expression and knockdown of DLEU1, SMYD2, APOC1; measurement of glycolytic parameters (ECAR, OCR, lactate, GLUT1/HK2/LDHA); xenograft mouse model\",\n      \"journal\": \"Translational oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP and RIP establish epigenetic mechanism; functional rescue confirms pathway; single lab\",\n      \"pmids\": [\"37478669\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ZNF460 transcriptionally activates APOC1 by binding to the APOC1 promoter, and ZNF460-driven APOC1 upregulation promotes EMT and progression of gastric cancer cells.\",\n      \"method\": \"ChIP assay and luciferase reporter for ZNF460 binding to APOC1 promoter; ZNF460 knockdown and APOC1 rescue; EMT marker analysis; invasion/migration assays; xenograft tumor growth in vivo\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct promoter binding established by ChIP + luciferase reporter; functional rescue confirms axis; single lab\",\n      \"pmids\": [\"36563923\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"FOXM1 transcriptionally activates APOC1 by directly binding its promoter; the FOXM1/APOC1 axis drives cervical cancer cell proliferation, EMT, invasion, and M2 macrophage polarization, and APOC1 overexpression rescues the phenotype caused by FOXM1 knockdown.\",\n      \"method\": \"ChIP and luciferase reporter assay for FOXM1-APOC1 promoter interaction; FOXM1/APOC1 knockdown and APOC1 rescue; CCK-8, colony formation, wound healing, transwell assays; flow cytometry for M2 markers; mouse transplant tumor model\",\n      \"journal\": \"Mutation research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — promoter binding by ChIP + reporter; functional rescue places APOC1 downstream of FOXM1; single lab\",\n      \"pmids\": [\"40139083\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"ZKSCAN5 acts as a transcriptional repressor of APOC1 through direct promoter binding; APOC1 inhibits ferroptosis in prostate cancer by modulating cholesterol homeostasis via the PI3K/AKT/SREBP2/SLC1A5 signaling cascade; SREBP2 directly binds the SLC1A5 promoter.\",\n      \"method\": \"ChIP and Cut&Tag for ZKSCAN5-APOC1 promoter binding and SREBP2-SLC1A5 promoter binding; APOC1 knockdown/overexpression; ferroptosis assays; PI3K/AKT/SREBP2/SLC1A5 pathway western blot; xenograft mouse model\",\n      \"journal\": \"Journal of translational medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple ChIP/Cut&Tag experiments establish transcriptional hierarchy; pathway validated by western blot; single lab\",\n      \"pmids\": [\"41029397\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Knockdown of Apoc1 overcomes sorafenib resistance in esophageal cancer cells by promoting ferroptosis via upregulation of ROS and MDA and downregulation of GSH; this effect is mediated through GPX4, as GPX4 manipulation rescues Apoc1 knockdown-induced ferroptosis.\",\n      \"method\": \"shRNA lentiviral Apoc1 knockdown; MTT cell viability; ROS/MDA/GSH measurement; GPX4 western blot; erastin and sorafenib treatment; rescue with GPX4 overexpression; xenograft mouse model\",\n      \"journal\": \"Gene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — GPX4 rescue experiment mechanistically places APOC1 upstream of GPX4 in ferroptosis regulation; in vivo validation; single lab\",\n      \"pmids\": [\"37804922\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"APOC1 expressed in macrophages promotes pulmonary metastasis of colorectal cancer by activating STAT3 signaling, which drives CCL2 and CCL5 chemokine secretion; antibodies against CCL2 and CCL5 partially block the pro-metastatic effects of APOC1-expressing macrophages.\",\n      \"method\": \"APOC1 knockdown in macrophages; co-culture with CRC cells; transwell invasion/migration and EMT assays; ELISA for CCL2 and CCL5; CCL2/CCL5 neutralizing antibody blockade; STAT3 phosphorylation western blot; in vivo pulmonary metastasis mouse model\",\n      \"journal\": \"International immunopharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional epistasis (antibody blockade of downstream chemokines) and STAT3 pathway analysis; in vivo validation; single lab\",\n      \"pmids\": [\"40194454\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1986,\n      \"finding\": \"APOC1 and APOE genes are tandemly oriented on chromosome 19q and separated by ~6 kb of genomic DNA, with a single lambda phage clone carrying both genes, suggesting possible coordinate regulation of the apolipoprotein gene cluster.\",\n      \"method\": \"Somatic cell hybrid panel with chromosome 19 long/short arm translocation; Southern blotting with cDNA probes; isolation of overlapping cosmid/lambda phage clones spanning APOC1 and APOE\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct molecular cloning establishes gene organization; highly cited foundational study\",\n      \"pmids\": [\"3459164\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1988,\n      \"finding\": \"The HpaI restriction site polymorphism associated with familial dysbetalipoproteinemia is located 317 bp upstream of the APOC1 transcription initiation site in the APOC1 promoter region.\",\n      \"method\": \"Molecular cloning and DNA sequencing of genomic clones; construction of detailed restriction map of the APOE-APOC1-APOC2 gene cluster by overlapping cosmid analysis\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct sequencing and physical mapping; foundational structural study\",\n      \"pmids\": [\"2897845\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"In zebrafish, apoc1 expression in microglia is uniquely regulated by RXR receptors and is differentially controlled by LXR/RXR versus PPAR/RXR modulating compounds (LXR/RXR modulation affects apoc1 while PPAR/RXR affects apoeb), establishing a distinct transcriptional regulatory circuit for apoc1 in CNS microglia.\",\n      \"method\": \"In situ hybridization (HCR) for apoc1 in zebrafish CNS; pharmacological LXR/RXR and PPAR/RXR modulation; RT-qPCR quantification of apoc1 and apoeb transcripts in whole heads and individual microglia\",\n      \"journal\": \"Biology open\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological dissection with in situ single-cell quantification; zebrafish ortholog; single lab\",\n      \"pmids\": [\"34878094\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"APOC1 encodes a small exchangeable apolipoprotein that (1) inhibits lipoprotein lipase (LPL)-mediated TG-lipolysis and stimulates hepatic VLDL production, causing hypertriglyceridemia; (2) inhibits cholesteryl ester transfer protein (CETP) activity via HDL-association; (3) activates LCAT; (4) binds phospholipids through C-terminal aromatic residues F42/F46; (5) promotes HCV membrane fusion via direct interaction with the viral surface; and (6) in cancer contexts, drives tumor progression and macrophage M2 polarization through direct binding to STAT3, CD163/CD206, MTCH2, and Clusterin, and by modulating ferroptosis through GPX4 and the PI3K/AKT/SREBP2/SLC1A5 axis, while its transcription is regulated upstream by FOXM1, ZNF460, and ZKSCAN5, and epigenetically by SMYD2/H3K4me3.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"APOC1 encodes a small exchangeable apolipoprotein that functions as a central modulator of lipoprotein metabolism by directly inhibiting lipoprotein lipase (LPL)-mediated triglyceride lipolysis, stimulating hepatic VLDL production, activating lecithin:cholesterol acyltransferase (LCAT), and inhibiting cholesteryl ester transfer protein (CETP) activity when associated with HDL [PMID:15576844, PMID:16537968, PMID:179085, PMID:16282639]. Its C-terminal amphipathic α-helix, particularly aromatic residues F42 and F46, mediates phospholipid binding essential for lipoprotein association, and HDL-bound APOC1 promotes hepatitis C virus membrane fusion through interaction with the HCV E2 glycoprotein hypervariable region 1 [PMID:18984910, PMID:17761674]. In cancer contexts, APOC1 directly binds and activates STAT3 to drive epithelial–mesenchymal transition and metastasis, promotes M2 macrophage polarization through interactions with CD163/CD206 and subsequent CCL2/CCL5 chemokine secretion, and suppresses ferroptosis upstream of GPX4 and through the PI3K/AKT/SREBP2/SLC1A5 axis [PMID:32826950, PMID:35914680, PMID:37804922, PMID:41029397]. APOC1 transcription is activated by FOXM1, ZNF460, and the lncRNA DLEU1/SMYD2-H3K4me3 axis, repressed by ZKSCAN5, and post-transcriptionally regulated by intracellular cholesterol levels [PMID:40139083, PMID:36563923, PMID:37478669, PMID:41029397, PMID:15694932].\",\n  \"teleology\": [\n    {\n      \"year\": 1976,\n      \"claim\": \"Establishing that APOC1 is an activator of LCAT resolved a fundamental question about which apolipoproteins regulate this central enzyme in reverse cholesterol transport.\",\n      \"evidence\": \"In vitro LCAT activation assay using chemically synthesized full-length 57-residue apoC-I versus native protein\",\n      \"pmids\": [\"179085\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of LCAT activation by apoC-I not determined\", \"Relative contribution of apoC-I vs apoA-I to LCAT activation in vivo not established\"]\n    },\n    {\n      \"year\": 1986,\n      \"claim\": \"Mapping APOC1 in tandem with APOE on chromosome 19q established the physical organization of the apolipoprotein gene cluster, raising the possibility of coordinate transcriptional regulation.\",\n      \"evidence\": \"Somatic cell hybrid panel and overlapping lambda phage/cosmid clones spanning APOC1 and APOE\",\n      \"pmids\": [\"3459164\", \"2897845\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Coordinate regulatory elements between APOE and APOC1 not functionally tested in this study\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Demonstrating that apoC-I directly inhibits LPL-mediated triglyceride lipolysis — rather than blocking hepatic receptor-mediated lipoprotein clearance — resolved the principal mechanism of apoC-I-induced hypertriglyceridemia.\",\n      \"evidence\": \"In vitro LPL lipolysis assay with purified apoC-I; [³H]TG-VLDL clearance in APOC1 transgenic and apoE-deficient × APOC1 transgenic mice with lactoferrin blockade of hepatic clearance\",\n      \"pmids\": [\"15576844\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of LPL inhibition by apoC-I not resolved\", \"Relative quantitative contribution of LPL inhibition vs VLDL overproduction in humans unknown\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Two independent studies established that APOC1 secretion is post-transcriptionally regulated by intracellular cholesterol and that HDL-associated apoC-I is a potent endogenous CETP inhibitor, linking APOC1 to both metabolic sensing and HDL-cholesterol homeostasis.\",\n      \"evidence\": \"HepG2 cholesterol/TG loading with paired mRNA and protein measurements; human apoA-I/CETP double-transgenic rat model with CETP activity assay on reconstituted lipoproteins\",\n      \"pmids\": [\"15694932\", \"16282639\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular mechanism of cholesterol-dependent post-transcriptional regulation of apoC-I not identified\", \"Structural determinants of CETP inhibition by apoC-I not defined\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Graded apoC-I gene dose experiments in apoE-null mice revealed that endogenous apoC-I raises VLDL-TG through two independent mechanisms — stimulating hepatic VLDL production and attenuating LPL activity — quantifying the dual contribution for the first time.\",\n      \"evidence\": \"apoe−/−apoc1−/−, apoe−/−apoc1+/−, and apoe−/−apoc1+/+ mice with hepatic VLDL-TG/apoB production rates and [³H]TG-VLDL clearance\",\n      \"pmids\": [\"16537968\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which apoC-I stimulates hepatic VLDL assembly not elucidated\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Showing that HDL-associated apoC-I directly promotes HCV membrane fusion — dependent on the E2 HVR1 domain — extended APOC1 function beyond lipid metabolism to host–pathogen interaction.\",\n      \"evidence\": \"HCVcc/HCVpp infectivity, membrane fusion kinetics, binding assays, and HVR1 mutant viruses\",\n      \"pmids\": [\"17761674\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Precise binding interface between apoC-I and HCV E2 not structurally resolved\", \"In vivo relevance in human HCV infection not directly tested\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Identification of F42 and F46 in the C-terminal amphipathic helix as critical phospholipid-binding residues provided the first molecular-level understanding of how apoC-I associates with lipoprotein surfaces.\",\n      \"evidence\": \"Site-directed mutagenesis, DMPC binding Kd, sedimentation velocity AUC, and TEM of discoidal complexes\",\n      \"pmids\": [\"18984910\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"High-resolution structure of apoC-I–lipid complex not available\", \"How lipid binding relates to LPL inhibition or CETP inhibition structurally is unknown\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Discovery that APOC1 directly binds and activates STAT3 to drive EMT and metastasis in ccRCC — including via exosomal transfer to endothelial cells — established a new oncogenic signaling axis for this apolipoprotein.\",\n      \"evidence\": \"APOC1 knockdown/overexpression in ccRCC lines; exosome isolation and transfer; STAT3 phosphorylation; DPP-4 inhibitor suppression of metastasis\",\n      \"pmids\": [\"32826950\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct APOC1-STAT3 binding interface not mapped\", \"Whether DPP-4 acts on APOC1 directly or indirectly not resolved\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Multiple studies converged to show that APOC1 in macrophages drives M2 polarization through CD163/CD206 interaction and controls tumor immune microenvironment composition; APOC1 knockout in mice reverses M2 polarization via ferroptosis and enhances anti-tumor immunity.\",\n      \"evidence\": \"scRNA-seq; co-IP of APOC1 with CD163 and CD206; co-culture assays; APOC1−/− mouse tumor models with immune cell profiling\",\n      \"pmids\": [\"35914680\", \"36108528\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Ferroptosis pathway link in macrophage polarization not fully reconstituted biochemically\", \"Whether APOC1-CD163/CD206 interaction is direct or lipid-mediated not distinguished\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Identification of ZNF460 as a direct transcriptional activator of APOC1 and LXR/RXR-dependent regulation of apoc1 in zebrafish microglia began to define the transcription factor network controlling APOC1 expression in different cell types.\",\n      \"evidence\": \"ChIP and luciferase reporter for ZNF460 binding to APOC1 promoter; pharmacological LXR/RXR modulation with in situ hybridization in zebrafish\",\n      \"pmids\": [\"36563923\", \"34878094\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Integration of multiple transcription factors (ZNF460, FOXM1, ZKSCAN5) into a unified regulatory model not achieved\", \"Species-specific differences in transcriptional regulation not resolved\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"A series of studies established that APOC1 suppresses ferroptosis through distinct mechanisms in different cancers — via GPX4 in esophageal cancer and via MTCH2-dependent metabolic rewiring in osteosarcoma — linking APOC1 to cell death resistance and drug sensitivity.\",\n      \"evidence\": \"GPX4 rescue of APOC1-knockdown-induced ferroptosis; co-IP of APOC1 with MTCH2 and metabolic rescue experiments; sorafenib resistance models\",\n      \"pmids\": [\"37804922\", \"36911382\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether APOC1 directly binds GPX4 or acts upstream indirectly is unknown\", \"Unifying mechanism of ferroptosis suppression across cancer types not established\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Epigenetic activation of APOC1 was shown to occur via lncRNA DLEU1 recruitment of SMYD2 to deposit H3K4me3 at the APOC1 promoter, directly linking epigenetic remodeling to APOC1-driven glycolysis in gastric cancer.\",\n      \"evidence\": \"RIP and RNA pulldown for DLEU1-SMYD2; ChIP-PCR for SMYD2 and H3K4me3 at APOC1 promoter; glycolytic parameter measurement; xenograft model\",\n      \"pmids\": [\"37478669\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether this epigenetic mechanism operates outside gastric cancer is unknown\", \"Relationship between SMYD2-mediated activation and other transcription factors (ZNF460, FOXM1) not tested\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"FOXM1 was identified as a direct transcriptional activator and ZKSCAN5 as a direct repressor of APOC1, while APOC1 was shown to inhibit ferroptosis via PI3K/AKT/SREBP2/SLC1A5 signaling and to drive M2 macrophage polarization via STAT3-CCL2/CCL5 secretion, further detailing the tumor-promoting signaling network downstream of APOC1.\",\n      \"evidence\": \"ChIP and Cut&Tag for FOXM1 and ZKSCAN5 at APOC1 promoter; ferroptosis assays with PI3K/AKT/SREBP2 pathway inhibition; STAT3 phosphorylation and CCL2/CCL5 neutralizing antibody experiments in macrophage co-cultures; in vivo tumor and metastasis models\",\n      \"pmids\": [\"40139083\", \"41029397\", \"40194454\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model connecting all upstream regulators and downstream effectors\", \"Clinical relevance of APOC1-targeting in cancer therapy not validated in human trials\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"The structural basis of APOC1's interactions with STAT3, LPL, CETP, and its multiple cancer-associated partners remains unresolved, and whether APOC1's lipid-binding and oncogenic functions are mechanistically linked or independent is unknown.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No high-resolution structure of APOC1 in complex with any protein partner\", \"Whether apoC-I's lipid-bound versus lipid-free state determines its signaling activities is untested\", \"In vivo relevance of APOC1-driven immune reprogramming in human cancer not established\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [2, 4]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 1, 5]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 1, 3, 5, 8]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [0, 1, 2, 5]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [9, 10, 21]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [8, 13, 19]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [10, 20]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [3, 15]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"STAT3\",\n      \"CETP\",\n      \"MTCH2\",\n      \"CLU\",\n      \"CD163\",\n      \"CD206\",\n      \"GPX4\",\n      \"USP40\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}